Cell Metab
GLP-1 agonist protects the liver—even without weight loss
Clinical Takeaway: Semaglutide may confer clinically meaningful liver benefits in patients with metabolic liver disease even when weight loss is modest, suggesting liver outcomes should factor into treatment decisions.
Semaglutide, a widely used GLP-1 receptor agonist, improves liver health through a direct hepatic mechanism that does not depend on weight loss, according to a new study published in Cell Metabolism. Using multiple mouse models of metabolic dysfunction–associated steatohepatitis (MASH), investigators showed that semaglutide reduced steatosis, fibrosis, and inflammatory signaling even in animals resistant to GLP-1–mediated weight loss.
Mechanistically, advanced molecular mapping revealed GLP-1 receptor expression in liver sinusoidal endothelial cells (LSECs) and CD8+ T cells—overturning the long‑held assumption that hepatocytes lack GLP-1 receptors. When GLP-1 receptors were selectively deleted from LSECs, semaglutide’s liver benefits were largely lost despite preserved weight reduction.
In one striking experiment, mice without LSEC GLP-1 receptors failed to show hepatic improvement despite losing up to 20% of body weight. Transcriptomic analyses suggested semaglutide shifts stressed LSECs toward an anti-inflammatory, hepatoprotective state.
“We’ve seen patients who lose very little weight still have major improvements in liver inflammation and scarring. Now we know why,” said lead author Daniel Drucker, MD.
The findings highlight a potential role for lower-dose GLP-1 therapy in liver disease, with implications for managing MASH beyond weight-centric outcomes.
Source: Gonzalez-Rellan MJ, et al. (2026, April 14). Cell Metab. The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors